Background {#Sec1}
==========

Selective digestive decontamination (SDD) is a prophylactic treatment for critically ill patients that is based on an oropharyngeal paste and enteral suspension containing antimicrobials, usually tobramycin, colistin, and an antifungal as well as an intravenous antibiotic, administered during the first 4 days of intensive care unit (ICU) admission (usually a second-generation cephalosporin). The aim of SDD is to prevent or eradicate, if present, the oropharyngeal and intestinal abnormal carriage of potentially pathogenic microorganisms, such as aerobic gram-negative bacilli (AGNB), methicillin-sensitive *Staphylococcus aureus*, and yeasts, in patients at risk for nosocomial infections \[[@CR1], [@CR2]\]. Once a patient has been successfully decolonized, the unaffected anaerobic flora would offer prevention against new colonization with potential pathogenic microorganisms. In critically ill patients, SDD has been proven to prevent severe infections \[[@CR1]--[@CR3]\] and to reduce mortality \[[@CR3], [@CR4]\], particularly in settings with a low prevalence of multidrug-resistant bacteria. However, the use of SDD is still a matter of debate, largely because of concerns that it may promote the emergence of antibiotic-resistant strains \[[@CR5], [@CR6]\]. Also, the effect of SDD in ICUs with endemic circulation of multidrug-resistant gram-negative bacilli MDR-GNB) remains controversial \[[@CR7], [@CR8]\]. We investigated whether long-term use of SDD was efficacious in reducing ICU-acquired MDR-GNB infection and also sought to determine its effect, including colistin- and tobramycin-resistant colonization as well as other nosocomial infections and subsequent antibiotic consumption, in a mixed ICU with a high endemic level of multidrug-resistant bacteria (MDRB).

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

We conducted a prospective cohort study in a 30-bed medical-surgical ICU of an acute care tertiary hospital in Las Palmas de Gran Canaria, Canary Islands, Spain. All consecutive patients admitted to the ICU between September 1, 2010, and September 30, 2015, were included. They were grouped into two consecutive cohorts before and after implementation of SDD. Data of both cohorts were collected prospectively. Patients admitted between September 1, 2010, and September 30, 2011, were included in the non-SDD cohort, and patients admitted between October 1, 2011, and September 30, 2015, were included in the SDD cohort. Since October 1, 2011, SDD measures have been systematically applied to all ICU patients expected to require tracheal intubation for more than 48 hours (SDD cohort). SDD was started when the "Pneumonia Zero" project began to be implemented among Spanish ICUs. In the "Pneumonia Zero" project, SDD was a highly recommended component of the ventilator-associated pneumonia (VAP) prevention bundle \[[@CR9]\]. The primary objective was to compare outcome measures between the non-SDD and SDD cohorts.

SDD protocol {#Sec4}
------------

SDD was started on the day of tracheal intubation and was given throughout the length of the ICU stay and until discharge from the ICU. Patients were treated three times daily with 1 g of an oral paste applied to the oral cavity. The composition per 1 g was 20 mg of 2% colistin, 30 mg of 3% tobramycin, and 20 mg of 2% nystatin. The patients also received a 14-ml suspension containing 140 mg of 1% colistin, 180 mg of 2% tobramycin, and 453.6 mg of 3.2% nystatin \[[@CR10]\], which was administered into the gut through a nasogastric tube. In tracheostomized patients, the oral paste was also applied on the skin surrounding the tracheostomy three times daily. Enteral vancomycin, 40 mg of 4% oropharyngeal paste, and 700 mg of vancomycin in digestive solution were added at the same 8-hour interval to all methicillin-resistant *Staphylococcus aureus* (MRSA) carriers, as well as to patients referred from elsewhere until MRSA noncarrier status was documented \[[@CR11]\]. All patients received systemic cefotaxime, 1 g every 8 hours, during the first 4 days of SDD therapy, except patients with infections on admission, who were treated with their antibiotics.

Endpoints {#Sec5}
---------

The primary endpoints of the study were the incidence of ICU-acquired infection caused by MDRB, the evolution of colistin- and tobramycin-resistant colonization, and the clinical impact of SDD on MDRB infections. Secondary endpoints were VAP, central line-associated primary bloodstream infection (CLABSI), secondary bloodstream infection (BSI), urinary tract infection, and antibiotic consumption.

Study procedures and definitions {#Sec6}
--------------------------------

Surveillance samples from the throat, rectum, tracheostomy, and pressure sores were collected on ICU admission and once weekly thereafter. Diagnostic samples from tracheal aspirates, peripheral blood, urine, or wounds were obtained at the physician's discretion. Antimicrobial susceptibility testing was performed with the VITEK-2 system (bioMérieux, Inc., Durham, NC, USA) \[[@CR12]\], with breakpoints defined according to the Clinical and Laboratory Standards Institute \[[@CR13]\] and the European Committee on Antimicrobial Susceptibility Testing \[[@CR14]\] guidelines. Infections caused by MDRB included the following:*Enterobacteriaceae* spp. resistant to ceftazidime and/or aminoglycosides and/or ciprofloxacin with extended-spectrum β-lactamase (ESBL) producing bacteria*Pseudomonas aeruginosa* resistant to ceftazidime and/or aminoglycosides and/or ciprofloxacin and/or imipenemMRSAAny strain of *Acinetobacter* spp. resistant to carbapenemsGram-negative bacteria resistant to three or more antimicrobial families*Clostridium difficile*Vancomycin-resistant *Enterococcus* spp.

Imported MDRB infection was considered when cultures of surveillance or diagnostic samples were positive within 48 hours of ICU admission. ICU-acquired MDRB infection was defined as isolation of a new strain that was not recovered in any of the samples taken during the first 48 hours of admission. Also, secondary endogenous infections were those preceded by gastrointestinal carriage of MDRB with identical antibiotic susceptibility patterns and exogenous infections when the infecting MDRB was isolated in diagnostic samples without previous colonization \[[@CR15]\].

ICU-acquired infections were collected from the ENVIN-HELICS registry (National Nosocomial Infection Surveillance Study--Hospitals in Europe Link for Infection Control through Surveillance), which is a nationwide ongoing multicenter data collection system designed to record invasive device-related infections in ICU patients (http://hws.vhebron.net/envin-helics/). Diagnostic criteria established by the ENVIN-HELICS project were used \[[@CR16]\]. The diagnosis of VAP included the following:

1\. Sequential chest x-rays or computed tomographic (CT) scans with an image suggestive of pneumonia (two or more radiographs or CT scans in the presence of underlying cardiac or pulmonary disease)

2\. Fever (\> 38 °C) and/or leukocytosis (≥ 12,000 white blood cells \[WBC\]/mm^3^) or leukopenia (≤ 4000 WBC/mm^3^)

3\. At least one of the following:

a\. New-onset purulent sputum or change in the characteristics of sputum

b\. Cough, dyspnea, or tachycardia

c\. Rales or bronchial breath sounds on auscultation, ronchi, wheezing

d\. Worsening gas exchange

Other infections were diagnosed according to the Centers for Disease Control and Prevention definitions \[[@CR17]\] when applicable to ICU patients.

Ethics {#Sec7}
------

Our ICU participated in the ENVIN-HELICS national registry, and we used this registry for prospective data collection during the study \[[@CR18]\]. Baseline data collection started in 2010. The ENVIN-HELICS registry was approved by the ethics committees of the majority of participating ICUs and was declared a registry of healthcare interest by the Spanish Ministry of Health, Social Services and Equality in 2014. The ENVIN-HELICS registry was also approved by our hospital's ethics committee. We applied SDD in the context of the Spanish national "Pneumonia Zero" project \[[@CR9]\], the framework for implementing SDD, which is supported by the Spanish Ministry of Health, Social Policy and Equality through a contract with the Spanish Society of Critical Care Medicine and Coronary Units (number 0100/2010/0784). The study protocol was approved by the Clinical Research Ethics Committee of Hospital del Mar (Barcelona, Spain), which was the national reference committee.

Statistical analysis {#Sec8}
--------------------

Categorical variables are expressed as frequencies and percentages, and quantitative variables are expressed as mean ± SD or median and IQR (25th--75th percentiles) as appropriate. Percentages were compared with the χ^2^ test, means with Student's *t* test, and medians with the Wilcoxon test for independent data. Statistically significant variables in the univariate analysis were introduced in a multivariate logistic regression model, with selection of variables based on a complete enumeration algorithm and the Bayes information criterion. The models were summarized as coefficients (β), SE, *P* values (likelihood ratio test), and ORs, which were estimated by 95% CIs.

For each ICU-acquired infection, the incidence per 1000 days of exposure in each cohort and the corresponding relative risks (RRs) were obtained by Poisson regression analysis. Specifically, for the *i*th cohort determined by hospital, year, and month, we denote by *m*~*i*~ the number of events and by *d*~*i*~ the number of days of exposition (for all patients). A random effects Poisson model \[[@CR19]\] was considered, which assumes that, *m*~*i*~\~*Poisson*(*υ*~*i*~*μ*~*i*~) is:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \log {\mu}_i=\log {d}_i+\alpha +\beta \bullet {SDD}_i $$\end{document}$$where *υ*~1~, ..., *υ*~*k*~ are continuous positive valued *i*dd random variables such that *E*\[*υ*~*i*~\] = 1 and var(*υ*~*i*~) = *τ*. *SDD* is 1/0 according presence/absence of SDD. The parameter *τ* is the overdispersion. The RR deduced from the model is *RR* = exp *β*. The model was estimated by the likelihood method and summarized by the RRs, which were estimated by 95% CIs. Statistical significance was set at *P* ≤ 0.05. Data were analyzed using the R package, version 3.3.1 (R Development Core Team, 2016) \[[@CR20]\].

Results {#Sec9}
=======

During the 5-year study period, 3948 critically ill patients were admitted to the ICU, and ICU-acquired infection (VAP, CLABSI, secondary BSI, urinary tract infection) was diagnosed in 368 of them (7.8%). Of a total of 994 patients admitted to the ICU between September 2010 and September 2011, 110 patients had ICU-acquired infection in the non-SDD cohort. Of the 3948 patients admitted between October 2011 and September 2015, SDD was administered to 1998 (50.6%), and 258 developed an ICU-acquired infection (SDD cohort) (Fig. [1](#Fig1){ref-type="fig"}). No complications related to the use of SDD were recorded.Fig. 1Patient flowchart. *SDD* Selective digestive tract decontamination

Results of univariate analysis are shown in Table [1](#Tab1){ref-type="table"}. Demographic data and the distribution of most variables were similar in both cohorts. In the non-SDD cohort, the percentage of patients with chronic obstructive pulmonary disease and CLABSI was significantly lower than in the SDD cohort. However, we observed significantly lower rates of infections caused by MRDB, including *Acinetobacter* spp., other GNB and ESBL-producing multidrug-resistant bacteria, VAP, and secondary BSI, in the SDD cohort than in the non-SDD cohort. A significantly higher number of patients with CLABSI in the SDD cohort than in the non-SDD cohort was found. ICU-acquired infections caused by *C. difficile* or vancomycin-resistant *Enterococcus* spp. did not occur. In the multivariate analysis, SDD was found to be a protective factor against ICU-acquired infections caused by *Acinetobacter* spp. and MDR-GNB (Table [2](#Tab2){ref-type="table"}). In the multivariate logistic regression model for MDRB infection, renal replacement therapy (OR, 2.130; 95% CI, 1.346--3.372; *P* = 0.001) was an independent risk factor for MDRB infection, whereas SDD was a protective factor (OR, 0.491; 95% CI, 0.305--0.790; *P* \<  0.001).Table 1Results of univariate analysisVariablesNon-SDD cohort (*n* = 110)SDD cohort (*n* = 258)*P* valueMale sex74 (67.3)166 (64.3)0.589Age, years, mean ± SD59.5 ± 15.860.7 ± 16.40.539APACHE II score on admission, mean ± SD21.2 ± 7.722.0 ± 7.70.345Glasgow Coma Scale score, median (IQR)15 (8--15)14.5 (8--15)0.098Diagnosis on ICU admission0.289 Medical79 (71.8)190 (73.6) Scheduled surgery10 (9.1)33 (12.8) Emergency surgery21 (19.1)35 (13.6)Septic response0.399 Sepsis57 (52.8)110 (45.45) Septic shock51 (47.2)132 (54.55)Prior surgery18 (16.4)37 (14.3)0.618Urgent surgery34 (30.9)70 (27.1)0.461Trauma patients17 (15.5)31 (12.0)0.370Current smokers21 (19.1)31 (27.4)0.141Underlying illness Diabetes mellitus34 (30.9)86 (33.3)0.650 Coronary artery disease19 (17.3)45 (17.4)0.969 Chronic liver disease6 (5.5)18 (7.0)0.588 Chronic obstructive lung disease9 (8.2)43 (16.7)0.032 Solid neoplasm10 (9.1)26 (10.1)0.771 Chronic renal failure40 (36.4)56 (21.7)0.003 Renal replacement therapy34 (30.9)91 (35.3)0.419 Parenteral nutrition26 (23.6)50 (19.4)0.356 Immunosuppression8 (7.3)22 (8.5)0.687 Malnutrition12 (10.9)24 (9.3)0.635ICU-acquired infection VAP59 (53.6)102 (39.5)0.013 CLABSI26 (23.6)106 (41.1)0.001 Secondary BSI31 (28.2)47 (18.2)0.023 Urinary tract infection29 (26.4)73 (28.3)0.705Infections caused by MDRB Gram-negative bacilli12 (10.9)8 (3.1)0.002 *Acinetobacter* spp.13 (11.8)3 (1.2)\<  0.001 ESBL-producing MDRB38 (34.5)62 (24.0)0.038 *Pseudomonas aeruginosa*10 (9.1)23 (8.9)0.957 Methicillin-resistant *Staphylococcus aureus*4 (3.6)5 (1.9)0.460ICU stay, days, median (IQR)28 (16--45)33 (17--50)0.192ICU mortality36 (32.7)85 (33.2)0.929*Abbreviations: SDD* Selective digestive tract decontamination, *ICU* Intensive care unit, *APACHE* Acute Physiology and Chronic Health Evaluation, *VAP* Ventilator-associated pneumonia, *CLABSI* Central line-associated bloodstream infection, *BSI* Bloodstream infection, *MDRB* Multidrug-resistant bacteria, *ESBL* Extended-spectrum β-lactamaseData are expressed as frequency and percent unless otherwise statedTable 2Results of multivariate logistic regression analysis for selective digestive tract decontaminationVariable*P* valueOR (95% CI)CLABSI0.0032.218 (1.307 to 3.764)*Acinetobacter* spp.\< 0.0010.091 (0.025 to 0.329)MDR-GNB0.0010.204 (0.079 to 0.527)*CLABSI* Central line-associated bloodstream infection, *MDR-GNB* Multidrug-resistant gram-negative bacilli

Treatment with SDD was associated with a significant reduction of the RR for ICU-acquired infections caused by MDRB, VAP, and secondary BSI (Table [3](#Tab3){ref-type="table"}). The probabilities of acquiring infections caused by MDRB, VAP, and secondary BSI were 69%, 57%, and 66% lower, respectively, in the SDD cohort than in the non-SDD cohort.Table 3Intensive care unit-acquired infection ratesNon-SDD cohort (*n* = 110)SDD cohort (*n* = 258)*P* valueRisk ratio (95% CI)VAP/MV days Number of VAP63110\< 0.0010.437 (0.320 to 0.595) Days of MV611224,432 VAP/1000 MV days10.34.5Urinary tract infection/urinary catheter days Number of urinary tract infections33970.1100.725 (0.488 to 1.076) Days of indwelling urinary catheter870735,312 Urinary infections/1000 catheter days3.792.75CLABSI/CVC days Number of CLABSI0.8021.056 (0.690 to 1.615) Days of CVC724930,631 CLABSI/1000 CVC days3.593.9Secondary BSI/ICU days Number of secondary BSI4357\< 0.0010.349 (0.237 to 0.516) ICU days of stay917637,857 Secondary BSI/1000 ICU days4.691.64MDRB/ICU days Number of MDRB infections88112\< 0.0010.308 (0.233 to 0.408) ICU days of stay917637,857 MDRB infections/1000 ICU days9.592.96*Abbreviations: SDD* Selective digestive tract decontamination, *VAP* Ventilator-associated pneumonia, *MV* Mechanical ventilation, *CLABSI* Central line-associated bloodstream infection, *CVC* Central venous catheter, *BSI* Bloodstream infection, *MDRB* Multidrug-resistant bacteria

The consumption of nine antimicrobial agents commonly used in critically ill patients for treating MDRB, expressed as defined daily dose per 100 bed-days in the ICU, also showed a marked reduction after implementation of the SDD prophylactic strategy (Table [4](#Tab4){ref-type="table"}). During the study period, other maneuvers directed toward reducing the use of antimicrobials were not applied.Table 4Antibiotic consumption during the study periodDrugNon-SDD period (1 year)SDD period (4 years)1st year2nd year3rd year4th yearLevofloxacin59.0138.1050.7943.9613.89Meropenem43.0932.4632.3027.911.10Imipenem25.0810.2012.576.063.15Colistin19.1710.7812.134.980.43Vancomycin7.234.956.966.562.47Tobramycin10.323.691.891.870.55Amikacin3.134.283.103.082.47Ceftazidime7.295.485.1210.935.80Ciprofloxacin9.6112.858.508.628.45Cefotaxime6.0122.622.322.722.7*SDD* Selective digestive tract decontaminationData are expressed as defined daily dose per 100 bed-days in the intensive care unit

Of a total of 3948 patients admitted to the ICU during the 4-year period of implementation of the SDD treatment, 285 showed surveillance samples colonized by colistin- or tobramycin-resistant pathogens. As shown in Table [5](#Tab5){ref-type="table"}, there were increases of colonization resistance to colistin and tobramycin at ICU admission. Also, as shown in Table [5](#Tab5){ref-type="table"}, the estimated rates adjusted to 100 patients with SDD decreased in the fourth year for tobramycin-resistant colonization and increased from 1.6 to 1.8 for colistin-resistant colonization in the third and fourth years of the study. The colistin- and tobramycin-acquired increasing rates of colonization resistance in the ICU by 1000 days and adjusted by the rate of resistances at admission were 0.82 (95% CI, 0.56 to 1.95; not statistically significant \[NS\]) and 1.13 (95% CI, 0.75 to 1.70; NS), respectively. The highest estimated rates of colistin- and tobramycin-resistant colonization by 1000 days in the ICU were 1.2 and 1.1 per 1000 days of ICU stay, respectively (Table [6](#Tab6){ref-type="table"}). A summary of the study findings is shown in Fig. [2](#Fig2){ref-type="fig"}.Table 5Colonization in surveillance samples by colistin- and tobramycin-resistant pathogensVariablesSDD period (between October 2011 and September 2015)Total1st year2nd year3rd year4th year(*n* = 285)(*n* = 59)(*n* = 56)(*n* = 69)(*n* = 101)Male sex, %66.767.871.460.967.2Age, years, mean ± SD60.7 ± 15.056.2 ± 14.461.0 ± 16.061.3 ± 12.462.4 ± 16.1Total patients394810671069851961Patients with SDD1998522381430665Colistin Resistance at ICU admission113 (39.6)5 (8.5)17 (30.4)30 (43.5)61 (60.4) Development of resistance30 (10.5)3 (5.1)8 (14.3)7 (10.1)12 (11.9)Observed (at ICU admission) Rate/100 patients2.860.471.593.536.35 Rate/100 patients SDD5.660.964.466.989.17Estimated (acquired in ICU) Rate/100 patients0.760.280.750.821.25 Rate/100 patients SDD1.50.572.11.631.8Tobramycin Resistance at ICU admission151 (52.9)17 (6.0)32 (11.2)34 (11.9)68 (23.9) Development of resistance30 (10.5)1 (0.4)3 (1.1)15 (5.3)11 (3.9)Observed (at ICU admission) Rate/100 patients3.821.592.993.997.08 Rate/100 patients SDD7.563.268.47.9110.23Estimated (acquired in ICU)-- Rate/100 patients0.760.090.281.761.14 Rate/100 patients SDD1.50.190.793.491.65*ICU* Intensive care unit, *SDD* Selective digestive tract decontaminationTable 6Evolution of rates of resistance to colistin and tobramycin in ICU, by 1000 daysResistancePeriod1st year2nd year3rd year4th year(*n* = 59)(*n* = 56)(*n* = 69)(*n* = 101)Patient-days9228858310,7319315ColistinAt admission5 (8.5)17 (30.4)30 (43.5)61 (60.4)Acquired in ICU3 (5.1)8 (14.3)7 (10.1)12 (11.9)Acquired in ICU, by 1000 days0.3250.9320.6521.288Acquired in ICU, by 1000 days and adjusted by rate of resistance at admission^a^0.2780.2280.1870.153TobramycinAt admission17 (6.0)32 (11.2)34 (11.9)68 (23.9)Acquired in ICU1 (0.4)3 (1.1)15 (5.3)11 (3.9)Acquired in ICU, by 1000 days0.1080.3501.3981.181Acquired in ICU, by 1000 days and adjusted by rate of resistance at admission^a^0.1440.1620.1820.205*ICU* Intensive care unitThe increasing rate of colistin- and tobramycin-acquired colonization resistance in the ICU by 1000 days and adjusted by the rate of resistance at admission was 0.82 (95% CI, 0.56 to 1.95; not statistically significant \[NS\]). *P* value for the goodness-of-fit test was 0.427. For tobramycin, the increasing rate was 1.13 (95% CI, 0.75 to 1.70; nonsignificant). *P* value for the goodness-of-fit test was 0.159^a^Adjusted for values corresponding to first year, namely number of patients, number of resistances at admission, and exposure daysFig. 2Summary of study findings. *ESBL* Extended-spectrum β-lactamase

Discussion {#Sec10}
==========

The main finding of the present study is a significant reduction in the incidence of infections caused by MDRB, including *Acinetobacter* spp., and other GNB- and ESBL-producing pathogens after 4 years of implementation of SDD in the daily care of ICU patients. Additionally, low rates of colistin- and tobramycin-resistant colonization were also observed in surveillance samples, with no significant increasing rate of ICU colonization resistance, by 1000 days, adjusted by the rate of resistances at ICU admission. In addition, VAP and secondary BSI infection rates declined. These findings were associated with a reduction in antibiotic consumption, which is a remarkable aspect of the present results.

We found a significant reduction of ICU-acquired infections caused by MDR-GNB following SDD in our ICU with a high level of antibiotic resistance before implementation of the SDD strategy. There is limited information on the effects of SDD in settings with high levels of MDRB. Four observational studies \[[@CR7], [@CR21]--[@CR23]\] and one small randomized controlled trial \[[@CR8]\] have been performed in ICUs where MDR-GNB were endemic or that had an outbreak of certain species of MDR-GNB. In these studies, SDD was applied either as a systematic treatment \[[@CR21]--[@CR23]\] or as a targeted approach for identified carriers \[[@CR7], [@CR8]\]. Most of these previous studies examined the effect of SDD on elimination or persistence of carriage of resistant strains, but ecological outcomes were not reported. Moreover, heterogeneity regarding settings and designs prevented clear interpretation of the findings; in fact, SDD was found to be useful in three studies \[[@CR7], [@CR21], [@CR23]\] and failed in two of them \[[@CR8], [@CR22]\]. Brun-Buisson et al. \[[@CR7]\] reported that SDD reduced colonization or carrier status and infection during an outbreak of ESBL-producing *Klebsiella pneumoniae*. Our study confirms that SDD can be useful in an environment with high levels of MDR-GNB.

However, the present results are in accord with data of studies carried out in settings with low levels of antibiotic resistance, including findings of systematic reviews of randomized controlled trials \[[@CR3], [@CR4]\] and long-term observational studies \[[@CR24]--[@CR27]\], confirming that SDD does not increase resistance. We also observed a significant reduction of infections caused by ESBL-producing MDRB. Similarly, Saidel-Odes and coworkers \[[@CR28]\] reported that SDD decreased intestinal overgrowth of carbapenem-resistant *K. pneumoniae*. Zandstra et al. \[[@CR29]\] also found that SDD is efficacious in controlling colonization with ESBL-producing bacteria, and Tascini et al. \[[@CR30]\] showed that oral administration of gentamicin decontaminated the gastrointestinal tract and prevented infections caused by carbapenem-resistant *K. pneumoniae* strains producing *K. pneumoniae carbapenemase* (KPC)-type β-lactamase.

We also found a significant reduction of the incidence of infections caused by *Acinetobacter baumannii* and MDR-GNB. Similarly, in a randomized controlled study of 934 patients admitted to a surgical and medical ICU, of whom 466 were assigned to SDD and 468 to standard treatment (control subjects), colonization with gram-negative bacteria resistant to ceftazidime, ciprofloxacin, imipenem, polymyxin E, or tobramycin occurred in 16% of SDD patients and in 26% in the control group (*P* = 0.001) \[[@CR31]\]. In a crossover study using cluster randomization in 13 ICUs in the Netherlands, the rate of isolation of gram-negative bacteria from rectal swabs was lower with SDD than with selective oropharyngeal decontamination (SOD) \[[@CR4]\]. Also, SDD, as compared with standard care, was associated with a reduction of 57% of ICU-acquired bacteremia caused by glucose-nonfermenting gram-negative rods (*P. aeruginosa*, *Stenotrophomonas maltophilia*, and *Acinetobacter* spp.) and of 81% by *Enterobacteriaceae*, and these reductions were not accompanied by increases in intrinsic MDR-GNB colonization or infection \[[@CR4]\]. A further analysis showed that development of ICU-acquired bacteremia caused by highly resistant microorganisms was 59% less frequent with SDD than with standard care and 63% less frequent with SDD than with SOD \[[@CR32]\]. Recently, Camus et al. \[[@CR33]\] found that the incidence rate of multidrug-resistant AGNB was lower during SDD (1.59 per 1000 patient-days versus preintervention 5.43%; *P* \<  0.001) and also declined with time, concluding that a decontamination regimen did not favor the emergence of multidrug-resistant AGNB. In agreement with other studies, infections caused by *C. difficile* \[[@CR31]\] and vancomycin-resistant *Enterococcu*s spp. \[[@CR34]\] were not registered.

The use of SDD resulted in a significant reduction of VAP, which is consistent with previous observations. In a systematic review of randomized controlled trials of antibiotic prophylaxis in 6914 ICU patients collected from 36 trials, there was a significant reduction of respiratory tract infections in the treated group (OR, 0.28; 95% CI, 0.65 to 0.87) \[[@CR3]\]. Also, in a study of 4945 mechanically ventilated patients admitted between 2005 and 2013, the incidence of VAP per 1000 ventilator days declined significantly from 4.38 ± 1.64 before to 1.64 ± 0.43 after introduction of SOD/SDD in December 2010 (*P* = 0.007) \[[@CR35]\]. Implementation of SDD as the standard of care in ICUs is thus effective in preventing VAP.

A further remarkable finding of the study was a significant reduction of secondary BSI associated with the use of SDD. In a randomized study involving 16 Dutch ICUs, the proportion of ICU-acquired bacteremia by *Enterobacteriaceae* was lower for SDD than for SOD (OR, 0.38; 95% CI, 0.26 to 0.55; *P* \<  0.001) \[[@CR1]\]. In a systematic review of 51 randomized controlled trials conducted between 1987 and 2005, comprising 4079 patients treated with SDD and 3986 control subjects, SDD was associated with a reduction of overall and gram-negative BSIs of 27% and 61%, respectively, without affecting gram-positive BSIs \[[@CR2]\]. Furthermore, prophylactic treatment with SDD was a protective factor for infections caused by MRDB. In a systematic review and meta-analysis of 64 studies assessing the effect of SDD and SOD on antimicrobial resistance, no differences were found in the prevalence of colonization or infection with gram-positive antimicrobial-resistant pathogens (MRSA, vancomycin-resistant enterococci) and gram-negative bacilli resistant to aminoglycosides and fluoroquinolones \[[@CR36]\]. However, there was a reduction in polymyxin-resistant and third-generation cephalosporin-resistant gram-negative bacilli in recipients of SDD compared with those who did not receive the intervention. According to these data, the perceived risk of long-term harm related to SDD cannot be justified. The authors also conclude that the effect of SDD on ICU-level antimicrobial resistance rates is probably understudied. However, emergence of antimicrobial resistance is still a main objection to the widespread use of SDD in ICUs \[[@CR5], [@CR6], [@CR8]\].

Also, there is a controversy regarding the emergence of an increased resistance to colistin and tobramycin used as part of SDD. We found low rates of colistin- and tobramycin-resistant colonization in cultures of surveillance samples during the 4-year SDD. It is known that there may be nosocomial transmission of highly resistant microorganisms from one patient infected to another, with or without SDD, and that this can increase the number of patients with GNB-resistant colonization \[[@CR37]\]. As shown in Table [5](#Tab5){ref-type="table"}, there are increases of colonization resistance to colistin and tobramycin at ICU admission. Also, the estimated rates adjusted to 100 patients with SDD decreased in the fourth year for tobramycin-resistant colonization and showed a small increase from 1.6 to 1.8 for colistin-resistant colonization in the third and fourth years of the study. The colistin- and tobramycin-acquired increasing rates of colonization resistance in the ICU by 1000 days and adjusted by the rate of resistances at admission were 0.82 (95% CI, 0.56 to 1.95; NS) and 1.13 (95% CI, 0.75 to 1.70; NS), respectively. These findings mean that although there were increases in the rates of colistin- and tobramycin-resistant colonization, these increases could not be associated with SDD and may have been linked to the progressive rise of MDR-GNB at ICU admission over the 4 years of the study and also may have been due to a higher degree of nosocomial transmission of highly resistant microorganisms among ICU patients. The highest estimated rates of colistin- and tobramycin-resistant colonization by 1000 days at risk were 1.2 and 1.1 per 1000 days, respectively (Table [6](#Tab6){ref-type="table"}).

Colistin- and tobramycin-resistant colonization rates in our study were lower than 2.5/1000 patients days at risk, as shown in the study by Oostdijk et al. \[[@CR38]\]. Using two large cohorts of ICU patients, Oostdijk et al. demonstrated that the prolonged use of colistin, as part of SDD and SOD, was not associated with increased acquisition of colistin-resistant GNB in the respiratory tract. Moreover, acquisition rates of colistin-resistant GNB in the intestinal tract during SDD ranged from 1.2 to 3.2 per 1000 patient-days at risk. The overall conversion rate from colistin susceptibility to resistance in the intestinal tract was below 1 conversion per 1000 patient-days at risk. During SDD, though, these conversion rates ranged from 3.2 to 5.4 per 1000 days of colonization with GNB and from 15.5 to 12.6 per 1000 days of colonization with tobramycin-resistant GNB. Also, the use of meropenem appeared to be strongly associated with the development of meropenem resistance in *P. aeruginosa* with an adjusted HR of 11.1 (95% CI, 2.4--51.5), corresponding to 23 events of resistance acquisition per 1000 patient-days at risk. \[[@CR39]\]. On the basis of these findings, we concluded, as Oostdijk et al. \[[@CR38]\] did, that the rates of resistance acquisition for frequently used antibiotics were considerably higher than for acquisition of colistin resistance during topical use of this agent.

Our findings differ from those of previous studies showing no increase in acquisition of resistant flora to these agents over a 5-year period \[[@CR24]\] or no increases in the prevalence of resistance against colistin and tobramycin among gram-negative isolates during a mean of 7 years of SDD or SOD use \[[@CR40]\]. Noteboom et al. \[[@CR41]\] also observed that the percentages of antibiotic resistance with SDD and standard care were similar.

However, in a short course of SDD with colistin and gentamicin during an outbreak due to a KPC-2-producing *K. pneumoniae* strain, development of secondary resistance to colistin (19% increase in resistance rate) and gentamicin (45% increase) was found \[[@CR8]\]. Halaby et al. \[[@CR5]\] reported a significant relationship between use of SDD and tobramycin resistance as well as resistance to colistin among ESBL-producing pathogens. Brink et al. \[[@CR6]\] showed the emergence of KPC in *Enterobacteriaceae* and the selection of strains resistant to colistin. Of note, Silvestri et al. \[[@CR42]\], regarding data reported by Brink et al. \[[@CR6]\], argued that an inadequate dose of enteral antimicrobials in the SDD protocol was responsible for the failure of *K. pneumoniae* to decolonize and eventually become resistant to colistin. Failure associated with subtherapeutic doses of SDD may cause overgrowth of MDR-GNB, with increased spontaneous mutation leading to polyclonality and resistance \[[@CR43]\].

Associations between prolonged intravenous colistin use and development of colistin resistance have been reported from settings with high levels of carbapenemase-producing GNB \[[@CR44], [@CR45]\]. In contrast to facilitating resistance, SDD has been used successfully as a control measure in outbreak situations with ESBL-producing GNB \[[@CR7], [@CR46]\]. High intraluminal levels of topical antibiotics exceed minimum inhibitory concentrations of resistant pathogens, leading at least to temporary suppression, which reduces the risk of overgrowth and cross-transmission. However, there are several factors aside from SDD that produce GNB-resistant colonization. We did not find any MDR-GNB susceptible only to colistin in our study. Also, we observed decreased ICU global mortality over the course of the 4-year application of SDD.

Nevertheless, we think that SDD must be accompanied by careful monitoring of tobramycin and colistin resistance in GNB. We do so, as described in our protocol. We recommended screening weekly throughout the ICU stay.

Conclusions {#Sec11}
===========

SDD in an ICU setting with a high level of resistance was associated with a clinically relevant reduction of infections caused by MDRB, with low rates of colistin- and tobramycin-resistant colonization and a nonsignificant increasing rate of ICU colonization resistance by 1000 days, adjusted by the rate of resistance at ICU admission. SDD was also a protective factor against MDRB infection. Furthermore, VAP and secondary BSI were significantly decreased after SDD. Notably, a decrease in antimicrobial consumption was also observed.

AGNB

:   Aerobic gram-negative bacilli

APACHE

:   Acute Physiology and Chronic Health Evaluation

BSI

:   Bloodstream infection

CLABSI

:   Central line-associated bloodstream infection

CLSI

:   Clinical and Laboratory Standards Institute

CT

:   Computed tomographic

CVC

:   Central venous catheter

ENVIN

:   National Nosocomial Infection Surveillance Study

ESBL

:   Extended-spectrum β-lactamase

EUCAST

:   European Committee on Antimicrobial Susceptibility Testing

GNB

:   Gram-negative bacilli

HELICS

:   Hospitals in Europe Link for Infection Control through Surveillance

ICU

:   Intensive care unit

KPC

:   *Klebsiella pneumoniae* carbapenemase

MDRB

:   Multidrug-resistant bacteria

MDR-GNB

:   Multidrug-resistant gram-negative bacilli

MRSA

:   Methicillin-resistant *Staphylococcus aureus*

MV

:   Mechanical ventilation

NS

:   Nonsignificant

RR

:   Risk ratio

SDD

:   Selective digestive tract decontamination

SEMICYUC

:   Spanish Society of Critical Care Medicine and Coronary Units

SOD

:   Selective oropharyngeal decontamination

VAP

:   Ventilator-associated pneumonia

WBC

:   White blood cells

The authors thank Marta Pulido, MD, for editing the manuscript and for editorial assistance.

This study was awarded as one of the best communications in the 29th Annual Congress of the European Society of Intensive Care Medicine, Milan, Italy, October 1-5, 2016.

Availability of data and materials {#FPar3}
==================================

Please contact the authors for data requests.

CSR designed the study, drafted the manuscript, collected data, analyzed results, and discussed and supervised the registry. SHE collected and analyzed data, critically reviewed the manuscript, and supervised the registry. MAHV collected data and supervised the registry. LCB collected data and supervised the registry. PS performed statistical analysis and interpreted data. NSM collected data and critically reviewed the manuscript. FAC collected data and critically reviewed the manuscript. CFLV collected data. SRS designed the study, drafted the manuscript, analyzed results, interpreted data, and provided general supervision of the study. MCS collection of data and supervision of the registry. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar1}
==========================================

The ENVIN registry was approved by the ethics committees of the majority of participating ICUs, including our hospital, and was declared a registry of healthcare interest by the Spanish Ministry of Health, Social Services and Equality in 2014.

Consent for publication {#FPar2}
=======================

Not applicable, given the noninterventional nature of the study, because data were collected from the ENVIN-HELICS registry.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
